{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:24:07Z","timestamp":1786994647577,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ncl.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:28:13Z","timestamp":1752643693000},"page":"485-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring Beyond Mu"],"prefix":"10.1016","volume":"43","author":[{"given":"Brittany A.","family":"Henault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Wegrzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ncl.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.15585\/mmwr.mm7215a1","article-title":"Chronic pain among adults - United States, 2019-2021","volume":"72","author":"Rikard","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.001_bib2","first-page":"766","article-title":"Pharmacologic therapy for acute pain","volume":"87","author":"Blondell","year":"2013","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ncl.2025.05.001_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.580289","article-title":"Analgesic effect of acetaminophen: a review of known and novel mechanisms of action","volume":"11","author":"Ohashi","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ncl.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jama.2023.1080","article-title":"Association of FDA mandate limiting acetinominophen (Paracetamol) in prescription combination opioid products and subsequent hospitalizations and acute liver failure","volume":"9","author":"Orandi","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.001_bib6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamapediatrics.2020.3080","article-title":"Association of prenatal acetaminophen exposure measured in meconium with risk of attention-deficit\/hyperactivity disorder mediated by frontoparietal network brain connectivity","volume":"174","author":"Baker","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.001_bib7","article-title":"Diuretics, ACEIs, ARBs, and NSAIDs: a nephrotoxic combination","volume":"79","author":"Horn","year":"2013","journal-title":"Pharm Times"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1016\/j.ncl.2025.05.001_bib9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/030079907X210561","article-title":"Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization","volume":"23","author":"Sun","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ncl.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/JPR.S440802","article-title":"Identifying risk factors for cardiovascular events among active-duty service members and veterans prescribed nonsteroidal anti-inflammatory drugs (NSAIDs)","volume":"17","author":"Forbes","year":"2024","journal-title":"J Pain Res"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.001_bib11","first-page":"23","article-title":"CYP2C9 polymorphism and use of oral nonsteroidal anti-inflammatory drugs","volume":"54","author":"Kathuria","year":"2021","journal-title":"US Pharm"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pmr.2020.01.002","article-title":"Nonsteroidal antiinflammatory drugs for acute and chronic pain","volume":"31","author":"Atkinson","year":"2020","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.ncl.2025.05.001_bib13","article-title":"A review of skeletal muscle relaxants for pain management","author":"Raouf","year":"2016","journal-title":"Prac Pain Mgmt"},{"key":"10.1016\/j.ncl.2025.05.001_bib14","series-title":"Goodman and Gilman's Manual of Pharmacology and Therapeutics","article-title":"Neuromuscular junction and autonomic ganglia; nicotine, muscle relaxants, and spasmolytics","author":"Hibbs","year":"2016"},{"key":"10.1016\/j.ncl.2025.05.001_bib15","unstructured":"Ratto D, Joyner RW. Dantrolene. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535398\/."},{"issue":"S1","key":"10.1016\/j.ncl.2025.05.001_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032372","article-title":"Botox (onabotulinumtoxinA) mechanism of action","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.001_bib17","first-page":"365","article-title":"Choosing a skeletal muscle relaxant","volume":"78","author":"See","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ncl.2025.05.001_bib18","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1172\/JCI43766","article-title":"Central modulation of pain","volume":"120","author":"Ossipov","year":"2010","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pneurobio.2006.08.001","article-title":"Noradrenergic pain modulation","volume":"80","author":"Pertovaara","year":"2006","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.ncl.2025.05.001_bib20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJM199205073261904","article-title":"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy","volume":"326","author":"Max","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.001_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jcpt.12534","article-title":"Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia","volume":"42","author":"Raouf","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ncl.2025.05.001_bib22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ncl.2025.05.001_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.840452","article-title":"Associations of antidepressants with atrial fibrillation and ventricular arrhythmias: a systematic review and meta-analysis","volume":"9","author":"Cao","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3\u20134","key":"10.1016\/j.ncl.2025.05.001_bib24","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.ncl.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ncl.2025.05.001_bib26","series-title":"Tricyclic antidepressant Chemistry, dose, indication, receptor specificity, & pharmacokinetics","author":"Flynn","year":"2015"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/2049463720912496","article-title":"Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice","volume":"14","author":"Chincholkar","year":"2020","journal-title":"Br J Pain"},{"key":"10.1016\/j.ncl.2025.05.001_bib28","article-title":"Comparing gabapenting to pregabalin for neuopathic pain","author":"Morgenson","year":"2016","journal-title":"Pain Dr"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mus.23314","article-title":"The role of sodium channels in chronic pain","volume":"46","author":"Levinson","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2025.05.001_bib30","article-title":"Analgesic potential of voltage gated sodium channel modulators for the management of pain","volume":"75","author":"McDougall","year":"2024","journal-title":"ScienceDirect"},{"key":"10.1016\/j.ncl.2025.05.001_bib31","series-title":"Carbamazepine","year":"2018"},{"key":"10.1016\/j.ncl.2025.05.001_bib32","series-title":"Oxtellar XR (oxcarbazepine) [prescribing information]","year":"2018"},{"key":"10.1016\/j.ncl.2025.05.001_bib33","series-title":"Topamax (topiramate) [prescribing information]","year":"2019"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.001_bib34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/bja\/aer260","article-title":"Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch","volume":"107","author":"Anand","year":"2011","journal-title":"Br J Anaesth"},{"issue":"10","key":"10.1016\/j.ncl.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1093\/pm\/pnab113","article-title":"Progressive response to repeat application of capsaicin 179 mg (8% w\/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications","volume":"22","author":"Freynhagen","year":"2021","journal-title":"Pain Med"},{"key":"10.1016\/j.ncl.2025.05.001_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Nav1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2025.05.001_bib37","unstructured":"Vertex announces FDA acceptance of new drug application for suzetrigine for the treatment of moderate-to-severe acute pain, 30 Jul 2024, Vertex Pharmaceuticals Inc. Accessed: 10 October 2024. Available at: https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-acceptance-new-drug-application-suzetrigine."},{"key":"10.1016\/j.ncl.2025.05.001_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","article-title":"NMDA receptors in nervous system diseases","volume":"74","author":"Zhou","year":"2013","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.ncl.2025.05.001_bib39","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7150\/ijbs.6426","article-title":"Glutamate, glutamate receptors, and downstream signaling pathways","volume":"9","author":"Willard","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/bja\/57.2.197","article-title":"Comparative pharmacology of the ketamine isomers. Studies in volunteers","volume":"57","author":"White","year":"1985","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2025.05.001_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.ncl.2025.05.001_bib42","first-page":"76","article-title":"Ketamine \u2013 more mechanisms of action than just NMDA blockade","volume":"4","author":"Sleigh","year":"2014","journal-title":"Trends Anaesth Crit Care"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.001_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00044011-200929050-00004","article-title":"Development of a sublingual\/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study","volume":"29","author":"Chong","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.001_bib45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.12264","article-title":"The absolute bioavailability of racemic ketamine from a novel sublingual formulation","volume":"77","author":"Rolan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/bja\/77.2.203","article-title":"Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children","volume":"77","author":"Malinovsky","year":"1996","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.001_bib47","first-page":"260","article-title":"Pharmacokinetics of ketamine in man","volume":"24","author":"Wieber","year":"1975","journal-title":"Anaesthesist"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of mu-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.001_bib49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejp.1153","article-title":"Ketamine for chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"22","author":"Michelet","year":"2018","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.001_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","article-title":"Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Orhurhu","year":"2019","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11916-018-0664-x","article-title":"The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis","volume":"22","author":"Zhao","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.ncl.2025.05.001_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fnhum.2016.00612","article-title":"Ketamine: 50 years of modulating the mind","volume":"10","author":"Li","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.ncl.2025.05.001_bib53","series-title":"Memantine [prescribing information]","year":"2017"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.001_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/fcp.12316","article-title":"Memantine for the treatment of general neuropathic pain: a narrative review","volume":"32","author":"Pickering","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ncl.2025.05.001_bib55","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/JPR.S389957","article-title":"Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series","volume":"16","author":"McKenzie-Brown","year":"2023","journal-title":"J Pain Res"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.001_bib56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1573397113666170321120329","article-title":"Low dose naltrexone in the treatment of fibromyalgia","volume":"14","author":"Metyas","year":"2018","journal-title":"Curr Rheumatol Rev"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.001_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose Naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.ncl.2025.05.001_bib59","article-title":"Low dose naltrexone: is it really worth the hype?","volume":"48","author":"Singla","year":"2023","journal-title":"ASRA Pain Medicine News"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T02:17:33Z","timestamp":1752805053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0733861925000209"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.001","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Beyond Mu","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}